Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease

Antioxidants and Redox Signaling

Volumn 17, Issue 12, 2012, Pages 1764-1784

  Garcia Garcia, Aracely ^a   Zavala Flores, Laura ^a   Rodriguez Rocha, Humberto ^a   Franco, Rodrigo ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DOPAMINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; METALLOTHIONEIN; METHIONINE SULFOXIDE REDUCTASE; PEROXIREDOXIN; THIOL; THIOREDOXIN; TRANSCRIPTION FACTOR;

DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; HYDROXYLATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NITROSATION; NITROSYLATION; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL DEATH; DOPAMINERGIC NEURONS; HUMANS; OXIDATION-REDUCTION; PARKINSON DISEASE; SIGNAL TRANSDUCTION; SULFHYDRYL COMPOUNDS;

EID: 84867716087     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4501     Document Type: Review

References (201)

1. Abou-Sleiman PM, Muqit MM, and Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7: 207-219, 2006.. (Pubitemid 43292466)
2. Adam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal 7: 1140-1149, 2005.. (Pubitemid 41232509)
3. Aizenman E, McCord MC, Saadi RA, Hartnett KA, and He K. Complex role of zinc in methamphetamine toxicity in vitro. Neuroscience 171: 31-39, 2010..
4. Akazawa YO, Saito Y, Hamakubo T, Masuo Y, Yoshida Y, Nishio K, Shichiri M, Miyasaka T, Iwanari H, Mochizuki Y, Kodama T, Noguchi N, and Niki E. Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals. Neurosci Lett 483: 201-205, 2010..
5. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, and Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69: 1326-1329, 1997.. (Pubitemid 27364859)
6. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, and Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196-1203, 1997.. (Pubitemid 27364841)
7. Albrecht P, Lewerenz J, Dittmer S, Noack R, Maher P, and Methner A. Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc-as a neuro-protective drug target. CNS Neurol Disord Drug Targets 9: 373-382, 2010..
8. Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, Dachsel J, Melrose H, Farrer M, Wszolek ZK, Dickson DW, and Tan EK. Mutations in LRRK2 increase phosphorylation of per-oxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 32: 1390-1397, 2011..
9. Aon-Bertolino ML, Romero JI, Galeano P, Holubiec M, Badorrey MS, Saraceno GE, Hanschmann EM, Lillig CH, and Capani F. Thioredoxin and glutaredoxin system pro-teins-immunolocalization in the rat central nervous system. Biochim Biophys Acta 1810: 93-110, 2011..
10. Aoyama K, Matsumura N, Watabe M, and Nakaki T. Oxidative stress on EAAC1 is involved in MPTP-induced glutathione depletion and motor dysfunction. Eur J Neu-rosci 27: 20-30, 2008..
11. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, and Ischiropoulos H. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Proc Natl Acad Sci U S A 95: 7659-7663, 1998.. (Pubitemid 28293309)
12. Bai J, Nakamura H, Hattori I, Tanito M, and Yodoi J. Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells. Neurosci Lett 321: 81-84, 2002.. (Pubitemid 34185504)
13. Balijepalli S, Tirumalai PS, Swamy KV, Boyd MR, Mieyal JJ, and Ravindranath V. Rat brain thioltransferase: regional distribution, immunological characterization, and localization by fluorescent in situ hybridization. J Neurochem 72: 1170-1178, 1999.. (Pubitemid 29085033)
14. Barone MC, Sykiotis GP, and Bohmann D. Genetic activation of Nrf2 signaling is sufficient to ameliorate neurode-generative phenotypes in a Drosophila model of Parkinson's disease. Dis Model Mech 4: 701-707, 2011..
15. Beer SM, Taylor ER, Brown SE, Dahm CC, Costa NJ, Runswick MJ, and Murphy MP. Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mito-chondrial membrane thiol proteins: implications for mito-chondrial redox regulation and antioxidant defense. J Biol Chem 279: 47939-47951, 2004.. (Pubitemid 39540945)
16. Benhar M, Forrester MT, and Stamler JS. Protein deni-trosylation: enzymatic mechanisms and cellular functions. Nat Rev Mol Cell Biol 10: 721-732, 2009..
17. Bensadoun JC, Mirochnitchenko O, Inouye M, Aebischer P, and Zurn AD. Attenuation of 6-OHDA-induced neurotox-icity in glutathione peroxidase transgenic mice. Eur J Neu-rosci 10: 3231-3236, 1998.. (Pubitemid 29070619)
18. Biswas M and Chan JY. Role of Nrf1 in antioxidant response element-mediated gene expression and beyond. Toxicol Appl Pharmacol 244: 16-20, 2010..
19. Bocca B, Alimonti A, Senofonte O, Pino A, Violante N, Petrucci F, Sancesario G, and Forte G. Metal changes in CSF and peripheral compartments of parkinsonian patients. J Neurol Sci 248: 23-30, 2006.. (Pubitemid 44647278)
20. Bove J, Prou D, Perier C, and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2: 484-494, 2005.. (Pubitemid 41444882)
21. Brigelius-Flohe R and Flohe L. Basic principles and emerging concepts in the redox control of transcription factors. Antioxid Redox Signal 15: 2335-2381, 2011..
22. Burton NC, Kensler TW, and Guilarte TR. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotox-icology 27: 1094-1100, 2006.. (Pubitemid 44838961)
23. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, and Cookson MR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 101: 9103-9108, 2004.. (Pubitemid 38781618)
24. Cannon JR and Greenamyre JT. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog Brain Res 184: 17-33, 2010..
25. Castello PR, Drechsel DA, and Patel M. Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. J Biol Chem 282: 14186-14193, 2007.. (Pubitemid 47100444)
26. Chau KY, Cooper JM, and Schapira AH. Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int 57: 525-529, 2010..
27. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, and Johnson JA. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci U S A 106: 2933-2938, 2009..
28. Chinta SJ and Andersen JK. Reversible inhibition of mito-chondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic Biol Med 41: 1442-1448, 2006.. (Pubitemid 44466728)
29. Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, and Andersen JK. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neurosci 27: 13997-14006, 2007.. (Pubitemid 351377875)
30. Chinta SJ, Rajagopalan S, Butterfield DA, and Andersen JK. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neurosci Lett 402: 137-141, 2006.. (Pubitemid 43766441)
31. Choi DY, Liu M, Hunter RL, Cass WA, Pandya JD, Sullivan PG, Shin EJ, Kim HC, Gash DM, and Bing G. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 4: e5482, 2009..
32. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, and Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279: 13256-13264, 2004.. (Pubitemid 38445905)
33. Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, and Li L. Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280: 11648-11655, 2005.. (Pubitemid 40418479)
34. Choi WS, Kruse SE, Palmiter RD, and Xia Z. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci U S A 105: 15136-15141, 2008..
35. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, and Dawson TM. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304: 1328-1331, 2004.. (Pubitemid 38697430)
36. Chung RS, Hidalgo J, and West AK. New insight into the molecular pathways of metallothionein-mediated neuroprotection and regeneration. J Neurochem 104: 14-20, 2008.. (Pubitemid 350265070)
37. Ciron C, Lengacher S, Dusonchet J, Aebischer P, and Schneider BL. Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet 2012 [Epub ahead of print]; DOI: 10.1093/hmg/ddr618..
38. Clark J, Clore EL, Zheng K, Adame A, Masliah E, and Simon DK. Oral N-acetyl-cysteine attenuates loss of dopa-minergic terminals in alpha-synuclein overexpressing mice. PLoS One 5: e12333, 2010..
39. Clark J and Simon DK. Transcribe to survive: transcrip-tional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal 11: 509-528, 2009..
40. Clements CM, McNally RS, Conti BJ, Mak TW, and Ting JP. DJ-1, a cancer-and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A 103: 15091-15096, 2006.. (Pubitemid 44583169)
41. Cohen G, Farooqui R, and Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci U S A 94: 4890-4894, 1997.. (Pubitemid 27214706)
42. Cox AG, Winterbourn CC, and Hampton MB. Mitochon-drial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem J 425: 313-325, 2010..
43. Cristovao AC, Choi DH, Baltazar G, Beal MF, and Kim YS. The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxid Redox Signal 11: 2105-2118, 2009..
44. Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Mel-amed E, Holmgren A, and Barzilai A. Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1. J Biol Chem 276: 1335-1344, 2001.. (Pubitemid 32096564)
45. Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Mel-amed E, Holmgren A, and Barzilai A. Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways. J Biol Chem 276: 21618-21626, 2001..
46. Danielson SR and Andersen JK. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med 44: 1787-1794, 2008..
47. Danielson SR, Held JM, Oo M, Riley R, Gibson BW, and Andersen JK. Quantitative mapping of reversible mi-tochondrial Complex I cysteine oxidation in a Parkinson disease mouse model. J Biol Chem 286: 7601-7608, 2011..
48. De Simoni S, Goemaere J, and Knoops B. Silencing of per-oxiredoxin 3 and peroxiredoxin 5 reveals the role of mito-chondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+. Neurosci Lett 433: 219-224, 2008..
49. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, and Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283: 9089-9100, 2008..
50. Dexter D, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, and Marsden CD. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet 2: 639-640, 1986.. (Pubitemid 16055627)
51. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, and Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389, 1989.. (Pubitemid 19037600)
52. Drechsel DA, Liang LP, and Patel M. 1-methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons. Toxicol Appl Pharmacol 220: 341-348, 2007.. (Pubitemid 46627847)
53. Drechsel DA and Patel M. Differential contribution of the mitochondrial respiratory chain complexes to reactive oxygen species production by redox cycling agents implicated in parkinsonism. Toxicol Sci 112: 427-434, 2009..
54. Ebadi M, Brown-Borg H, El Refaey H, Singh BB, Garrett S, Shavali S, and Sharma SK. Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease. Brain Res Mol Brain Res 134: 67-75, 2005.. (Pubitemid 40409496)
55. Fang J, Nakamura T, Cho DH, Gu Z, and Lipton SA. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc Natl Acad Sci U S A 104: 18742-18747, 2007.. (Pubitemid 350210767)
56. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, and Morley JE. The antioxi-dants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 84: 1173-1183, 2003.. (Pubitemid 36330669)
57. Fomenko DE, Marino SM, and Gladyshev VN. Functional diversity of cysteine residues in proteins and unique features of catalytic redox-active cysteines in thiol oxidore-ductases. Mol Cells 26: 228-235, 2008..
58. Foster MW, Hess DT, and Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 15: 391-404, 2009..
59. Franco R and Cidlowski JA. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 16: 1303-1314, 2009..
60. Franco R, Schoneveld OJ, Pappa A, and Panayiotidis MI. The central role of glutathione in the pathophysi-ology of human diseases. Arch Physiol Biochem 113: 234-258, 2007..
61. Gan L, Johnson DA, and Johnson JA. Keap1-Nrf2 activation in the presence and absence of DJ-1. Eur J Neurosci 31: 967-977, 2010..
62. Gao HM and Hong JS. Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol 94: 1-19, 2011..
63. Gao HM, Liu B, and Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of do-paminergic neurons. J Neurosci 23: 6181-6187, 2003.. (Pubitemid 36875618)
64. Gauthier MA, Eibl JK, Crispo JA, and Ross GM. Covalent arylation of metallothionein by oxidized dopamine products: a possible mechanism for zinc-mediated enhancement of dopaminergic neuron survival. Neurotox Res 14: 317-328, 2008..
65. Glaser CB, Yamin G, Uversky VN, and Fink AL. Methio-nine oxidation, alpha-synuclein and Parkinson's disease. Biochim Biophys Acta 1703: 157-169, 2005.. (Pubitemid 40170439)
66. Godoy JR, Funke M, Ackermann W, Haunhorst P, Oesteritz S, Capani F, Elsasser HP, and Lillig CH. Redox atlas of the mouse. Immunohistochemical detection of glutaredoxin-, peroxiredoxin-, and thioredoxin-family proteins in various tissues of the laboratory mouse. Biochim Biophys Acta 1810: 2-92, 2011..
67. Goemaere J and Knoops B. Peroxiredoxin distribution in the mouse brain with emphasis on neuronal populations affected in neurodegenerative disorders. J Comp Neurol 520: 258-280, 2011..
68. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, and Richardson RJ. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20: 239-247, 1999..
69. Greisen P, Jespersen JB, and Kepp KP. Metallothionein Zn(2 + )-and Cu(2 + )-clusters from first-principles calculations. Dalton Trans 41: 2247-2256, 2012..
70. Gunther V, Lindert U, and Schaffner W. The taste of heavy metals: gene regulation by MTF-1. Biochim Biophys Acta 2012. http: //dx.doi.org/10.1016/j. bbamcr.2012.01.005..
71. Hall A, Karplus PA, and Poole LB. Typical 2-Cys peroxir-edoxins- structures, mechanisms and functions. FEBS J 276: 2469-2477, 2009..
72. Hastings TG. The role of dopamine oxidation in mito-chondrial dysfunction: implications for Parkinson's disease. J Bioenerg Biomembr 41: 469-472, 2009..
73. Hastings TG, Lewis DA, and Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 93: 1956-1961, 1996.. (Pubitemid 26079862)
74. Hauser RA, Lyons KE, McClain T, Carter S, and Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 24: 979-983, 2009..
75. Henchcliffe C and Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4: 600-609, 2008..
76. Hickey P and Stacy M. Available and emerging treatments for Parkinson's disease: a review. Drug Des Devel Ther 5: 241-254, 2011..
77. Horowitz MP and Greenamyre JT. Gene-environment interactions in Parkinson's disease: the importance of animal modeling. Clin Pharmacol Ther 88: 467-474, 2010..
78. Hozumi I, Hasegawa T, Honda A, Ozawa K, Hayashi Y, Hashimoto K, Yamada M, Koumura A, Sakurai T, Kimura A, Tanaka Y, Satoh M, and Inuzuka T. Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J Neurol Sci 303: 95-99, 2011..
79. Hu X, Weng Z, Chu CT, Zhang L, Cao G, Gao Y, Signore A, Zhu J, Hastings T, Greenamyre JT, and Chen J. Peroxir-edoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J Neurosci 31: 247-261, 2011..
80. Hwang YP, Kim HG, Han EH, and Jeong HG. Me-tallothionein-III protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a PI3K and ERK/Nrf2-dependent manner. Toxicol Appl Pharmacol 231: 318-327, 2008..
81. Ishisaki A, Hayashi H, Suzuki S, Ozawa K, Mizukoshi E, Miyakawa K, Suzuki M, and Imamura T. Glutathione S-transferase Pi is a dopamine-inducible suppressor of dopamine-induced apoptosis in PC12 cells. J Neurochem 77: 1362-1371, 2001.. (Pubitemid 32523689)
82. Isobe C, Murata T, Sato C, and Terayama Y. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci 77: 1836-1843, 2005.. (Pubitemid 41058987)
83. Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernandez-Ruiz J, and Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 14: 2347-2360, 2011..
84. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 146: 6-13, 1993.. (Pubitemid 23251601)
85. Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 63: S13-S22, 2004.. (Pubitemid 39346707)
86. Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu RM, Forman HJ, and Andersen JK. Glutathione depletion in PC12 results in selective inhibition of mitochon-drial complex I activity. Implications for Parkinson's disease. J Biol Chem 275: 26096-26101, 2000..
87. Jiang LJ, Maret W, and Vallee BL. The glutathione redox couple modulates zinc transfer from metallothionein to zinc-depleted sorbitol dehydrogenase. Proc Natl Acad Sci U S A 95: 3483-3488, 1998.. (Pubitemid 28173154)
88. Kalivendi SV, Kotamraju S, Cunningham S, Shang T, Hillard CJ, and Kalyanaraman B. 1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem J 371: 151-164, 2003.. (Pubitemid 36458089)
89. Kang MJ, Gil SJ, and Koh HC. Paraquat induces alternation of the dopamine catabolic pathways and glutathione levels in the substantia nigra of mice. Toxicol Lett 188: 148-152, 2009..
90. Kannan R, Chakrabarti R, Tang D, Kim KJ, and Kaplowitz N. GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res 852: 374-382, 2000.. (Pubitemid 30035175)
91. Kannan R, Mittur A, Bao Y, Tsuruo T, and Kaplowitz N. GSH transport in immortalized mouse brain endothe-lial cells: evidence for apical localization of a sodium-dependent GSH transporter. J Neurochem 73: 390-399, 1999.. (Pubitemid 29289148)
92. Karunakaran S, Saeed U, Ramakrishnan S, Koumar RC, and Ravindranath V. Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. Brain Res 1185: 8-17, 2007.. (Pubitemid 350176571)
93. Kelada SN, Checkoway H, Kardia SL, Carlson CS, CostaMallen P, Eaton DL, Firestone J, Powers KM, Swanson PD, Franklin GM, Longstreth WT Jr., Weller TS, Afsharinejad Z, and Costa LG. 5¢ and 3¢ region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study. Hum Mol Genet 15: 3055-3062, 2006.. (Pubitemid 44530709)
94. Kenchappa RS, Diwakar L, Annepu J, and Ravindranath V. Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration. FASEB J 18: 1102-1104, 2004.. (Pubitemid 39561537)
95. Kenchappa RS and Ravindranath V. Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP. FASEB J 17: 717-719, 2003..
96. Khan FH, Sen T, and Chakrabarti S. Dopamine oxidation products inhibit Na+, K +-ATPase activity in crude syn-aptosomal-mitochondrial fraction from rat brain. Free Radic Res 37: 597-601, 2003.. (Pubitemid 36603669)
97. Kil IS and Park JW. Regulation of mitochondrial NADP+-dependent isocitrate dehydrogenase activity by glutathio-nylation. J Biol Chem 280: 10846-10854, 2005..
98. Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, and Beal MF. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. J Neurosci 20: 1-7, 2000.. (Pubitemid 30220485)
99. Krapfenbauer K, Engidawork E, Cairns N, Fountoulakis M, and Lubec G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res 967: 152-160, 2003.. (Pubitemid 36324297)
100. Kumari MV, Hiramatsu M, and Ebadi M. Free radical scavenging actions of metallothionein isoforms I and II. Free Radic Res 29: 93-101, 1998.. (Pubitemid 28451388)
101. Lee BC and Gladyshev VN. The biological significance of methionine sulfoxide stereochemistry. Free Radic Biol Med 50: 221-227, 2011..
102. Lee DW, Kaur D, Chinta SJ, Rajagopalan S, and Andersen JK. A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease. Antioxid Redox Signal 11: 2083-2094, 2009..
103. Lee JC, Gray HB, and Winkler Jr. Copper(II) binding to alpha-synuclein, the Parkinson's protein. J Am Chem Soc 130: 6898-6899, 2008.. (Pubitemid 351770110)
104. Lee YM, Park SH, Shin DI, Hwang JY, Park B, Park YJ, Lee TH, Chae HZ, Jin BK, Oh TH, and Oh YJ. Oxida-tive modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. J Biol Chem 283: 9986-9998, 2008..
105. Levy OA, Malagelada C, and Greene LA. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 14: 478-500, 2009..
106. Liang LP and Patel M. Iron-sulfur enzyme mediated mi-tochondrial superoxide toxicity in experimental Parkinson's disease. J Neurochem 90: 1076-1084, 2004.. (Pubitemid 39167341)
107. Lippoldt A, Padilla CA, Gerst H, Andbjer B, Richter E, Holmgren A, and Fuxe K. Localization of thioredoxin in the rat brain and functional implications. J Neurosci 15: 6747-6756, 1995..
108. Liu F, Hindupur J, Nguyen JL, Ruf KJ, Zhu J, Schieler JL, Bonham CC, Wood KV, Davisson VJ, and Rochet JC. Me-thionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults. Free Radic Biol Med 45: 242-255, 2008..
109. Liu F, Nguyen JL, Hulleman JD, Li L, and Rochet JC. Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. J Neurochem 105: 2435-2453, 2008.. (Pubitemid 351782273)
110. Liu HQ, Zhu XZ, and Weng EQ. Intracellular dopamine oxidation mediates rotenone-induced apoptosis in PC12 cells. Acta Pharmacol Sin 26: 17-26, 2005..
111. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, and Brundin P. Effect of mutant alpha-synuclein on dopa-mine homeostasis in a new human mesencephalic cell line. J Biol Chem 277: 38884-38894, 2002.. (Pubitemid 35154753)
112. Lotharius J and O'Malley KL. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 275: 38581-38588, 2000.. (Pubitemid 32009186)
113. Ma L, Cao TT, Kandpal G, Warren L, Fred Hess J, Seabrook GR, and Ray WJ. Genome-wide microarray analysis of the differential neuroprotective effects of antioxidants in neu-roblastoma cells overexpressing the familial Parkinson's disease alpha-synuclein A53T mutation. Neurochem Res 35: 130-142, 2010..
114. Magyar K, Szende B, Jenei V, Tabi T, Palfi M, and Szoko E. R-deprenyl: pharmacological spectrum of its activity. Neu-rochem Res 35: 1922-1932, 2010..
115. Martin HL and Teismann P. Glutathione-a review on its role and significance in Parkinson's disease. FASEB J 23: 3263-3272, 2009..
116. Massie A, Schallier A, Kim SW, Fernando R, Kobayashi S, Beck H, De Bundel D, Vermoesen K, Bannai S, Smolders I, Conrad M, Plesnila N, Sato H, and Michotte Y. Dopami-nergic neurons of system x(c)-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity. FASEB J 25: 1359-1369, 2011..
117. Mejias R, Villadiego J, Pintado CO, Vime PJ, Gao L, Toledo-Aral JJ, Echevarria M, and Lopez-Barneo J. Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice. J Neurosci 26: 4500-4508, 2006.. (Pubitemid 44315349)
118. Meloni G and Vasak M. Redox activity of alpha-synuclein-Cu is silenced by Zn-metallothionein-3. Free Radic Biol Med 50: 1471-1479, 2011..
119. Menegon A, Board PG, Blackburn AC, Mellick GD, and Le Couteur DG. Parkinson's disease, pesticides, and glutathi-one transferase polymorphisms. Lancet 352: 1344-1346, 1998.. (Pubitemid 28510915)
120. Meng F, Yao D, Shi Y, Kabakoff J, Wu W, Reicher J, Ma Y, Moosmann B, Masliah E, Lipton SA, and Gu Z. Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation. Mol Neu-rodegener 6: 34, 2011..
121. Michael GJ, Esmailzadeh S, Moran LB, Christian L, Pearce RK, and Graeber MB. Up-regulation of metallothionein gene expression in Parkinsonian astrocytes. Neurogenetics 12: 295-305, 2011..
122. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, and Shelton MD. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal 10: 1941-1988, 2008..
123. Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, and Nagai M. Dietary intake of metals and risk of Parkinson's disease: a case-control study in Japan. J Neurol Sci 306: 98-102, 2011..
124. Miyazaki I, Asanuma M, Hozumi H, Miyoshi K, and So-gawa N. Protective effects of metallothionein against do-pamine quinone-induced dopaminergic neurotoxicity. FEBS Lett 581: 5003-5008, 2007.. (Pubitemid 47531776)
125. Miyazaki I, Asanuma M, Kikkawa Y, Takeshima M, Murakami S, Miyoshi K, Sogawa N, and Kita T. Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity. Glia 59: 435-451, 2011..
126. Miyazaki I, Sogawa CA, Asanuma M, Higashi Y, Tanaka KI, Nakanishi T, and Ogawa N. Expression of metallothionein-III mRNA and its regulation by levodopa in the basal ganglia of hemi-parkinsonian rats. Neurosci Lett 293: 65-68, 2000..
127. Mudo G, Makela J, Liberto VD, Tselykh TV, Olivieri M, Piepponen P, Eriksson O, Malkia A, Bonomo A, Kairisalo M, Aguirre JA, Korhonen L, Belluardo N, and Lindholm D. Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci 69: 1153-1165, 2011..
128. Munoz AM, Rey P, Soto-Otero R, Guerra MJ, and Labandeira-Garcia JL. Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration. J Neurosci Res 76: 551-562, 2004.. (Pubitemid 38580470)
129. Nakamura K, Bindokas VP, Marks JD, Wright DA, Frim DM, Miller RJ, and Kang UJ. The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol Pharmacol 58: 271-278, 2000.. (Pubitemid 30497470)
130. Naoi M, Maruyama W, Yi H, Yamaoka Y, Shamoto-Nagai M, Akao Y, Gerlach M, Tanaka M, and Riederer P. Neu-romelanin selectively induces apoptosis in dopaminergic SH-SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component. J Neu-rochem 105: 2489-2500, 2008.. (Pubitemid 351782270)
131. Napolitano A, Manini P, and d'Ischia M. Oxidative chemistry of catecholamines and neuronal degeneration: an update. Cur Med Chem 18: 1832-1845, 2011..
132. Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm 109: 1159-1180, 2002.. (Pubitemid 35013715)
133. Oien DB, Shinogle HE, Moore DS, and Moskovitz J. Clearance and phosphorylation of alpha-synuclein are inhibited in methionine sulfoxide reductase a null yeast cells. J Mol Neurosci 39: 323-332, 2009..
134. Pai HV, Starke DW, Lesnefsky EJ, Hoppel CL, and Mieyal JJ. What is the functional significance of the unique location of glutaredoxin 1 (GRx1) in the intermembrane space of mitochondria? Antioxid Redox Signal 9: 2027-2033, 2007.. (Pubitemid 47622345)
135. Pall HS, Williams AC, Blake DR, Lunec J, Gutteridge JM, Hall M, and Taylor A. Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet 2: 238-241, 1987.. (Pubitemid 17101088)
136. Pan J, Xiao Q, Sheng CY, Hong Z, Yang HQ, Wang G, Ding JQ, and Chen SD. Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease. Neurochem Int 54: 418-425, 2009..
137. Park SW, Kim SH, Park KH, Kim SD, Kim JY, Baek SY, Chung BS, and Kang CD. Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson's disease. Neurosci Lett 363: 243-246, 2004..
138. Paulsen CE and Carroll KS. Orchestrating redox signaling networks through regulatory cysteine switches. ACS Chem Biol 5: 47-62, 2010..
139. Perry TL and Yong VW. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67: 269-274, 1986.. (Pubitemid 16038336)
140. Poole LB and Nelson KJ. Discovering mechanisms of signaling-mediated cysteine oxidation. Curr Opin Chem Biol 12: 18-24, 2008..
141. Ramachandiran S, Hansen JM, Jones DP, Richardson JR, and Miller GW. Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation. Toxicol Sci 95: 163-171, 2007.. (Pubitemid 44970055)
142. Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, Zweckstetter M, Griesinger C, Jovin TM, and Fernandez CO. Structural characterization of copper(II) binding to alpha-synuclein: insights into the bioinorganic chemistry of Parkinson's disease. Proc Natl Acad Sci U S A 102: 4294-4299, 2005.. (Pubitemid 40397105)
143. Richardson JR, Quan Y, Sherer TB, Greenamyre JT, and Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci 88: 193-201, 2005.. (Pubitemid 41548761)
144. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuert-zer C, Gainetdinov RR, Caron MG, Di Monte DA, and Federoff HJ. Behavioral and neurochemical effects of wildtype and mutated human alpha-synuclein in transgenic mice. Exp Neurol 175: 35-48, 2002.. (Pubitemid 34507908)
145. Ridet JL, Bensadoun JC, Deglon N, Aebischer P, and Zurn AD. Lentivirus-mediated expression of glutathione perox-idase: neuroprotection in murine models of Parkinson's disease. Neurobiol Dis 21: 29-34, 2006.. (Pubitemid 41817302)
146. Ritz BR, Manthripragada AD, Costello S, Lincoln SJ, Farrer MJ, Cockburn M, and Bronstein J. Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ Health Perspect 117: 964-969, 2009..
147. Roede JR, Hansen JM, Go YM, and Jones DP. Maneb and paraquat-mediated neurotoxicity: involvement of peroxir-edoxin/thioredoxin system. Toxicol Sci 121: 368-375, 2011..
148. Rojas P, Rojas-Castaneda J, Vigueras RM, Habeebu SS, Rojas C, Rios C, and Ebadi M. MPTP decreases MT-I mRNA in mouse striatum. Neurochem Res 25: 503-509, 2000.. (Pubitemid 30317683)
149. Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M, and Cuadrado A. Nrf2 regulates mi-croglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58: 588-598, 2010..
150. Rybnikova E, Damdimopoulos AE, Gustafsson JA, Spyrou G, and Pelto-Huikko M. Expression of novel antioxidant thioredoxin-2 in the rat brain. Eur J Neurosci 12: 1669-1678, 2000.. (Pubitemid 30258875)
151. Sabens EA, Distler AM, and Mieyal JJ. Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson's disease. Biochemistry 49: 2715-2724, 2010..
152. Sabens Liedhegner EA, Steller KM, and Mieyal JJ. Levo-dopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease. Chem Res Toxicol 24: 1644-1652, 2011..
153. Saeed U, Durgadoss L, Valli RK, Joshi DC, Joshi PG, and Ravindranath V. Knockdown of cytosolic glutaredoxin 1 leads to loss of mitochondrial membrane potential: implication in neurodegenerative diseases. PLoS One 3: e2459, 2008..
154. Saeed U, Ray A, Valli RK, Kumar AM, and Ravindranath V. DJ-1 loss by glutaredoxin but not glutathione depletion triggers Daxx translocation and cell death. Antioxid Redox Signal 13: 127-144, 2010..
155. Saini N, Georgiev O, and Schaffner W. The parkin mutant phenotype in the fly is largely rescued by metal-responsive transcription factor (MTF-1). Mol Cell Biol 31: 2151-2161, 2011..
156. Saito Y, Hamakubo T, Yoshida Y, Ogawa Y, Hara Y, Fuji-mura H, Imai Y, Iwanari H, Mochizuki Y, Shichiri M, Nishio K, Kinumi T, Noguchi N, Kodama T, and Niki E. Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients. Neurosci Lett 465: 1-5, 2009..
157. Schapira AH. Mitochondria in the aetiology and patho-genesis of Parkinson's disease. Lancet Neurol 7: 97-109, 2008.. (Pubitemid 350251942)
158. Sharma SK, El Refaey H, and Ebadi M. Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10. Brain Res Bull 70: 22-32, 2006.. (Pubitemid 43783378)
159. Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, Matsuno-Yagi A, Miller GW, and Greenamyre JT. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 100: 1469-1479, 2007.. (Pubitemid 46376213)
160. Shi M, Bradner J, Bammler TK, Eaton DL, Zhang J, Ye Z, Wilson AM, Montine TJ, and Pan C. Identification of glu-tathione S-transferase pi as a protein involved in Parkinson disease progression. Am J Pathol 175: 54-65, 2009..
161. Shiraga H, Pfeiffer RF, and Ebadi M. The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein. Neurochem Int 23: 561-566, 1993..
162. Sian-Hulsmann J, Mandel S, Youdim MB, and Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 118: 939-957, 2011..
163. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, and Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 348-355, 1994.. (Pubitemid 24280055)
164. Siebert A, Desai V, Chandrasekaran K, Fiskum G, and Jafri MS. Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. J Neurosci Res 87: 1659-1669, 2009..
165. Smeyne M, Boyd J, Raviie Shepherd K, Jiao Y, Pond BB, Hatler M, Wolf R, Henderson C, and Smeyne RJ. GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proc Natl Acad Sci U S A 104: 1977-1982, 2007.. (Pubitemid 46239889)
166. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sul-livan JD, Fung V, Smith RA, Murphy MP, and Taylor KM. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 25: 1670-1674, 2010..
167. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, and Langston JW. Rotenone, paraquat and Parkinson's disease. Environ Health Perspect 119: 866-872, 2011..
168. Tew KD, Manevich Y, Grek C, Xiong Y, Uys J, and Townsend DM. The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. Free Radic Biol Med 51: 299-313, 2011..
169. Thiruchelvam M, Prokopenko O, Cory-Slechta DA, Buckley B, and Mirochnitchenko O. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease pheno-type. J Biol Chem 280: 22530-22539, 2005.. (Pubitemid 40827911)
170. Thiruchelvam MJ, Powers JM, Cory-Slechta DA, and Richfield EK. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci 19: 845-854, 2004.. (Pubitemid 38297021)
171. Thornalley PJ and Vasak M. Possible role for metallothio-nein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim Biophys Acta 827: 36-44, 1985.. (Pubitemid 15125549)
172. Tsang AH, Lee YI, Ko HS, Savitt JM, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, and Chung KK. S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proc Natl Acad Sci U S A 106: 4900-4905, 2009..
173. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Ma-sliah E, Nomura Y, and Lipton SA. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurode-generation. Nature 441: 513-517, 2006.. (Pubitemid 44050153)
174. Umeda-Kameyama Y, Tsuda M, Ohkura C, Matsuo T, Namba Y, Ohuchi Y, and Aigaki T. Thioredoxin suppresses Parkin-associated endothelin receptor-like receptor-induced neurotoxicity and extends longevity in Drosophila. J Biol Chem 282: 11180-11187, 2007.. (Pubitemid 47100768)
175. Uversky VN, Li J, and Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276: 44284-44296, 2001..
176. Van Laar VS, Mishizen AJ, Cascio M, and Hastings TG. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis 34: 487-500, 2009..
177. Vance JM, Ali S, Bradley WG, Singer C, and Di Monte DA. Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology 31: 598-602, 2010..
178. Vitvitsky V, Thomas M, Ghorpade A, Gendelman HE, and Banerjee R. A functional transsulfuration pathway in the brain links to glutathione homeostasis. J Biol Chem 281: 35785-35793, 2006.. (Pubitemid 46041310)
179. von Otter M, Landgren S, Nilsson S, Celojevic D, Bergstrom P, Hakansson A, Nissbrandt H, Drozdzik M, Bialecka M, Kur-zawski M, Blennow K, Nilsson M, Hammarsten O, and Zetterberg H. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med Genet 11: 36, 2010..
180. Wang C, Liu L, Zhang L, Peng Y, and Zhou F. Redox reactions of the alpha-synuclein-Cu(2+) complex and their effects on neuronal cell viability. Biochemistry 49: 8134-8142, 2010..
181. Wassef R, Haenold R, Hansel A, Brot N, Heinemann SH, and Hoshi T. Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-like symptoms. J Neurosci 27: 12808-12816, 2007.. (Pubitemid 350159591)
182. West AK, Hidalgo J, Eddins D, Levin ED, and Aschner M. Metallothionein in the central nervous system: roles in protection, regeneration and cognition. Neurotoxicology 29: 489-503, 2008..
183. Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, and Pallanck LJ. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci U S A 102: 8024-8029, 2005.. (Pubitemid 40781056)
184. Wilk JB, Tobin JE, Suchowersky O, Shill HA, Klein C, Wooten GF, Lew MF, Mark MH, Guttman M, Watts RL, Singer C, Growdon JH, Latourelle JC, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Berg CJ, Sun M, Goldwurm S, Pezzoli G, Racette BA, Perlmutter JS, Parsian A, Baker KB, Giroux ML, Litvan I, Pramstaller PP, Nicholson G, Burn DJ, Chinnery PF, Vieregge P, Slevin JT, Cambi F, MacDonald ME, Gusella JF, Myers RH, and Golbe LI. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. Neurology 67: 2206-2210, 2006.. (Pubitemid 46035478)
185. Wilson MA. The role of cysteine oxidation in DJ-1 function and dysfunction. Antioxid Redox Signal 15: 111-122, 2011..
186. Winterbourn CC and Hampton MB. Thiol chemistry and specificity in redox signaling. Free Radic Biol Med 45: 549-561, 2008..
187. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, and Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 100: 6145-6150, 2003.. (Pubitemid 36576945)
188. Wu XF, Block ML, Zhang W, Qin L, Wilson B, Zhang WQ, Veronesi B, and Hong JS. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal 7: 654-661, 2005.. (Pubitemid 40563204)
189. Xie T, Tong L, McCann UD, Yuan J, Becker KG, Mechan AO, Cheadle C, Donovan DM, and Ricaurte GA. Identification and characterization of metallothionein-1 and-2 gene expression in the context of (+/-)3, 4-methylenediox-ymethamphetamine-induced toxicity to brain dopaminergic neurons. J Neurosci 24: 7043-7050, 2004.. (Pubitemid 39096370)
190. Yang W, Tiffany-Castiglioni E, Koh HC, and Son IH. Paraquat activates the IRE1/ASK1/JNK cascade associated with apoptosis in human neuroblastoma SH-SY5Y cells. Toxicol Lett 191: 203-210, 2009..
191. Yang W, Tiffany-Castiglioni E, Lee MY, and Son IH. Paraquat induces cyclooxygenase-2 (COX-2) implicated toxicity in human neuroblastoma SH-SY5Y cells. Toxicol Lett 199: 239-246, 2010..
192. Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, Uehara T, and Lipton SA. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A 101: 10810-10814, 2004.. (Pubitemid 38955824)
193. Yao Z and Wood NW. Cell death pathways in Parkinson's disease: role of mitochondria. Antioxid Redox Signal 11: 2135-2149, 2009..
194. Zecca L, Youdim MB, Riederer P, Connor JR, and Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863-873, 2004.. (Pubitemid 39482155)
195. Zeevalk GD, Manzino L, Sonsalla PK, and Bernard LP. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol 203: 512-520, 2007.. (Pubitemid 46149596)
196. Zeevalk GD, Razmpour R, and Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 62: 236-249, 2008.. (Pubitemid 351626446)
197. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, and Scherzer CR. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2: 52ra73, 2010..
198. Zhou W and Freed CR. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 280: 43150-43158, 2005.. (Pubitemid 43049281)
199. Zhou W, Long C, Reaney SH, Di Monte DA, Fink AL, and Uversky VN. Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim Biophys Acta 1802: 322-330, 2010..
200. Zhou W, Zhu M, Wilson MA, Petsko GA, and Fink AL. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J Mol Biol 356: 1036-1048, 2006.. (Pubitemid 43145955)
201. Zlokovic BV, Mackic JB, McComb JG, Weiss MH, Kaplo-witz N, and Kannan R. Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem Biophys Res Commun 201: 402-408, 1994.. (Pubitemid 24213740)